Clinical Trials Logo

Prostatic Neoplasm clinical trials

View clinical trials related to Prostatic Neoplasm.

Filter by:

NCT ID: NCT03343093 Completed - Prostatic Neoplasm Clinical Trials

Restore: Improving Sexual Outcomes of Gay and Bisexual Prostate Cancer Survivors

Start date: January 1, 2019
Phase: N/A
Study type: Interventional

Development and evaluation of an online intervention addressing sexual functioning in gay and bisexual men (GBM) after prostate cancer treatment.

NCT ID: NCT03289130 Completed - Prostatic Neoplasm Clinical Trials

Dietary Factors and Racial Disparities in Prostate Cancer Aggressiveness

PCaP
Start date: September 2004
Phase:
Study type: Observational

The North Carolina-Louisiana Prostate Cancer Project is a population-based case-only study of over 2,000 men newly diagnosed with prostate cancer designed to address racial differences in prostate cancer aggressiveness and survival through a comprehensive evaluation of social, individual, and tumor level influences on prostate cancer aggressiveness. Project 3 specifically aims to examine nutritional modulation of prostate cancer aggressiveness using dietary assessment and biomarker-based data on dietary factors.

NCT ID: NCT03183544 Completed - Prostatic Neoplasm Clinical Trials

Dosimetry and Safety Phase 1 Study With 68Ga-PSMA-11 Sterile Cold Kit

PSMA
Start date: January 24, 2019
Phase: Phase 1
Study type: Interventional

Prostate cancer is the most common cancer in men. Early detection of primary diseases and recurrence is crucial for patient counseling and management. Conventional imaging modalities (CT-MRI) are limited to detect recurrence. Choline-based PET/CT is currently widely used as primary staging tool in prostate cancer and in patients with suspicious recurrent disease. Compared to choline-based tracers, 68Ga-PSMA ligands have been shown to have a higher diagnostic efficacy and to increase the detection of metastases even at low PSA levels. The most widely used prostate-specific membrane antigen (PSMA) ligand is PSMA-11. A supplier, ANMI, has developed a kit formulation of PSMA-11 which will be test in this clinical trial.

NCT ID: NCT03104907 Completed - Clinical trials for Lower Urinary Tract Symptoms

Prostatic Artery Embolization for Obstructive Uropathy Due to Prostate Cancer

Start date: March 22, 2017
Phase: N/A
Study type: Interventional

The aim of this study is to investigate the safety and efficacy of prostatic artery embolization of patients with recurrent symptoms secondary to locally advanced prostatic cancer including pelvic pain, bleeding or need for permanent urinary catheter who are unfit for or refuse surgical treatment.

NCT ID: NCT03035487 Completed - Prostate Cancer Clinical Trials

Urology of Virginia Case Series

Start date: December 2016
Phase: N/A
Study type: Interventional

The investigational protocol describes a small case series designed to compare three imaging modalities for use in visualizing prostate cancer. The three modalities to be tested are: transrectal micro-ultrasound , and conventional resolution transrectal ultrasound (LR-TRUS) (both as implemented on ExactVu, the multi-frequency novel micro-ultrasound system under investigation), and multi-parametric MRI (mpMRI). These modalities will be used for guiding systematic (standard, random, extended sextant) plus image-guided targeted prostate biopsies among men with known cancer and an indication for prostate biopsy. In the case of mpMRI, biopsy will be performed under micro-ultrasound guidance with the radiology report used for targeting.

NCT ID: NCT02977143 Completed - Prostatic Neoplasm Clinical Trials

Positive End-expiratory Pressure-induced Increase in Central Venous Pressure as a Predictor of Fluid Responsiveness in Robot-assisted Laparoscopic Surgery

Start date: November 2016
Phase: N/A
Study type: Interventional

In urologic robotic surgery with steep Trendelenburg position, maintenance of cardiac preload and cardiac output is important for clinical prognosis. Previous studies reported the positive end-expiratory pressure (PEEP)-induced increase in central venous pressure (CVP) could be a accurate predictor of fluid responsiveness in cardiac surgical patients. The authors attempt to evaluate the predictability of PEEP-induced increase in CVP as well as stroke volume variation in urologic robotic surgery with Steep Trendelenburg position.

NCT ID: NCT02971995 Completed - Prostatic Neoplasm Clinical Trials

Trimodal (18)F-choline-PET/mpMRI/TRUS Targeted Prostate Biopsies

PROSTEPIRM
Start date: December 2014
Phase: N/A
Study type: Interventional

Prostate cancer is the first cancer in humans (25%). The most widely used tracer in oncology, the 18-Fluoro DeoxyGlucose does not allow the study of prostatic neoplasia. On the other hand, Choline, which is an amino alcohol, is involved in the synthesis of cell membranes and has an affinity for prostate cells. Its concentration is directly proportional to cell proliferation. The analogue of choline has the advantage of having a rapid and stable accumulation over time in cancer cells, with a rapid urinary excretion (4 minutes after injection). The goal of this study is to assess the feasibility and the accuracy for targeting image guided prostate biopsy to detect prostate cancer after Imaging fusion of choline-PET/CT compared to 1.5T multiparametric magnetic resonance imaging (mpMRI) with 3D-transrectal ultrasound (TRUS) .

NCT ID: NCT02967458 Completed - Prostatic Neoplasm Clinical Trials

Detection of High Grade Prostate Cancer With Subharmonic Ultrasound Imaging, A Pilot Study

Start date: February 1, 2017
Phase: Phase 2
Study type: Interventional

This is a phase II single center study using contrast-enhanced ultrasound to identify aggressive forms of prostate cancer with subharmonic imaging. The following are the study objectives: 1. To implement subharmonic imaging technology on a transrectal probe suitable for prostate imaging and biopsy 2. To demonstrate visualization of prostatic vascularity using subharmonic contrast-enhanced imaging. 3. To provide a preliminary estimate of the diagnostic accuracy of contrast-enhanced subharmonic imaging for detection of clinically significant PCa. The study will include 50 subjects who are scheduled for prostate biopsy. Each subject will receive an intravenous infusion of microbubble contrast material immediately prior to a prostate biopsy procedure. The study will demonstrate whether subharmonic imaging with a microbubble contrast agent allows for detection of clinically significant prostate cancer.

NCT ID: NCT02966535 Completed - Prostatic Neoplasm Clinical Trials

The Effect of Prolonged Inspiratory Time on Gas Exchange During Robot-assisted Laparoscopic Surgery With Steep Trendelenburg Position : A Crossover Randomized Clinical Trial

Start date: November 2016
Phase: N/A
Study type: Interventional

Gas exchange disturbance frequently occurs in steep Trendelenburg position during robot-assisted laparoscopic prostatectomy or cystectomy. Due to increased intrathoracic pressure and absorbed carbon dioxide (CO2) gas insufflated into abdominal cavity, hypercapnia as well as hypoxia may occur. Inverse ratio ventilation or prolonged inspiratory time during mechanical ventilation has been reported to be improve gas exchange in adult respiratory distress syndrome. The investigators attempt to test the hypothesis that prolonged inspiratory time may improve the gas exchange during robot-assisted laparoscopic urologic surgery.

NCT ID: NCT02729103 Completed - Prostatic Neoplasm Clinical Trials

Treatment Patterns in Metastatic Prostate Cancer

Start date: October 31, 2016
Phase: N/A
Study type: Observational

This study will evaluate treatment patterns, mortality, healthcare resource utilization, and costs in patients with prostate cancer with bone metastases (primary objectives). Additionally, this study will evaluate opioid/analgesic use among lines of therapy in this patient population (secondary objective). The study is descriptive in nature and is meant to provide a greater understanding of the patterns of therapy observed in real-world clinical practice (in the absence of clear guideline recommendations with regards to treatment sequencing), to contribute to a greater understanding of the major cost drivers (thus better-informing payers), and to examine real-world mortality in such patients.